文献速递主动脉外科瓣膜外科冠心病外科

微停搏液与4:1血停搏液在复杂心脏手术中的效果与成本节约

Microplegia vs 4:1 Blood Cardioplegia: Effectiveness and Cost Savings in Complex Cardiac Operations.
PubMed 文献 · Ann Thorac Surg · 2020-03-08

本研究比较了微停搏液与改良Buckberg停搏液在复杂多组件心脏手术中的安全性和有效性。通过倾向性匹配226对患者,发现微停搏液在心肌保护方面不劣于Buckberg停搏液,且显著减少晶体液用量和术中峰值血糖,并大幅降低停搏液成本。

要点

  • 微停搏液在复杂心脏手术中安全有效,心肌保护不劣于Buckberg停搏液。
  • 微停搏液显著减少停搏液中的晶体液用量和术中峰值血糖。
  • 微停搏液每例成本仅为Buckberg停搏液的1/26。

核心结论

  • 简化微停搏液技术在复杂多组件手术中不损害心肌保护或安全性,且具有多项优势。

研究设计与样本

  • 回顾性队列研究,2012年1月至2017年1月,242例接受微停搏液多组件手术,10512例接受改良Buckberg停搏液,倾向性匹配226对进行比较。

主要发现

  • 调整主动脉阻断时间后,术后肌钙蛋白T中位数组间无差异。
  • 微停搏液组停搏液晶体液用量平均27±8.0 mL/例,Buckberg组735±357 mL/例,P<.001。
  • 微停搏液组术中峰值血糖196±40 mg/dL,Buckberg组248±69 mg/dL,P<.001。
  • 两组院内死亡率(2.7% vs 2.2%,P=.8)、卒中(2.2% vs 3.6%,P=.4)、肾衰竭(8% vs 5.8%,P=.4)、延长通气(23% vs 24%,P=.7)、术后住院时间中位数(均8.1天,P>.9)及输血患者红细胞单位中位数(4单位 vs 3单位,P=.14)均无显著差异。
  • 微停搏液每例停搏液平均成本为Buckberg停搏液的1/26。

临床怎么用

  • 在复杂多组件心脏手术中可考虑使用简化微停搏液技术,以降低晶体液负荷和血糖,并节约成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microplegia has been studied during isolated coronary artery bypass grafting and valve surgery but not in more complex operations. Objectives of this study were to demonstrate safety and effectiveness of microplegia relative to Buckberg cardioplegia during these operations. METHODS: From January 2012 to January 2017, 242 patients underwent multicomponent operations with simplified microplegia delivered via syringe pump and 10,512 with modified Buckberg cardioplegia. Operations included aortic root, arch, or ascending aorta replacement in 424 (94%) patients, aortic valve surgery in 324 (72%) patients, and concomitant coronary artery bypass grafting in 47 (10%) patients. Outcomes were compared in 226 propensity-matched pairs. RESULTS: There was no difference in median postoperative troponin T between groups after adjusting for aortic clamp time. Microplegia patients received significantly less crystalloid with their cardioplegia (mean 27 ± 8.0 mL/operation vs 735 ± 357 mL/operation; P < .001) and had lower peak intraoperative glucose (196 ± 40 mg/dL vs 248 ± 69 mg/dL; P < .001). Microplegia and Buckberg groups had similar in-hospital mortality (2.7% [n = 6] vs 2.2% [n = 5]; P = .8), stroke (2.2% [n = 5] vs 3.6% [n = 8]; P = .4), renal failure (8% [n = 18] vs 5.8% [n = 13]; P = .4), prolonged ventilation (23% [n = 51] vs 24% [n = 54]; P = .7), median postoperative length of stay (both 8.1 days; P > .9), and median red cell units administered to patients requiring transfusion (4 units vs 3 units; P = .14). The mean cost of cardioplegia per case with microplegia was 1/26th that of Buckberg cardioplegia. CONCLUSIONS: Our simplified microplegia technique offers several advantages over Buckberg cardioplegia without compromising myocardial protection or safety in complex, multicomponent operations with extended aortic clamp times.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Borden RA, Ball C, Grady PM, et al. Microplegia vs 4:1 Blood Cardioplegia: Effectiveness and Cost Savings in Complex Cardiac Operations. Ann Thorac Surg. 2020. PMID: 32160958. doi:10.1016/j.athoracsur.2020.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。